ADVENTRX Appoints Vice President of Regulatory Affairs
March 13 2007 - 7:00AM
PR Newswire (US)
SAN DIEGO, March 13 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc., (AMEX:ANX), a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases,
announced today that it appointed Michele L. Yelmene to the new
position of vice president of regulatory affairs. Ms. Yelmene will
direct the execution of the Company's ongoing global regulatory
strategy and be responsible for all regulatory submissions for the
Company's product candidates. "Michele brings tremendous experience
in regulatory affairs management and product submissions for a
range of highly successful pharmaceutical and biological
therapies," said Evan M. Levine, ADVENTRX chief executive officer.
"Her role will be instrumental as we advance the development of
CoFactor(R) (ANX-510) and vinorelbine emulsion (ANX-530), and,
pending appropriate approvals, anticipate moving additional
products into the clinic this year." Michele Yelmene brings over 25
years of operational and project management, clinical and
scientific research and regulatory affairs experience in the
biotechnology and pharmaceutical industries. From 2002-2006, she
was Executive Director, Clinical and Regulatory Affairs and
Corporate Secretary for Perlan Therapeutics, a privately-held
company focused on development of recombinant protein-based drugs.
From 1998-2002, Ms. Yelmene was Director in Biomedical Operations
for Genzyme Corporation and from 1996-1998 she was Manager of
Medical and Regulatory Affairs for Mallinckrodt. During her career,
Ms. Yelmene was responsible for clinical development, preparation,
and presentation of 14 FDA-approved products and over 25
investigational new drug applications (INDs) for both
pharmaceutical and biologics-based therapies in the areas of viral
infections, respiratory, CNS, metabolic and endocrine diseases, and
lysosomal storage disorders. She has participated in meetings with
the FDA at all phases (pre-IND through Advisory Committee) of
clinical development. Ms. Yelmene is a member of the Regulatory
Affairs Professional Society, Drug Information Association and
Co-Chair of the FDA Committee at BIOCOM in San Diego. She received
a BS degree in Biology and BA degree in English Writing, both from
Rider University. About ADVENTRX Pharmaceuticals ADVENTRX
Pharmaceuticals is a biopharmaceutical research and development
company focused on commercializing proprietary product candidates
for the treatment of cancer and infectious diseases. The Company
seeks to improve the performance and safety of existing treatments
by addressing significant problems, such as drug metabolism and
bioavailability, excessive toxicity and treatment resistance. The
Company's lead product candidate, ANX-510 (CoFactor), is in Phase
III and Phase IIb clinical trials for the treatment of metastatic
colorectal cancer, as well as in a Phase II clinical trial for the
treatment of advanced breast cancer. More information can be found
on the Company's web site at http://www.adventrx.com/.
Forward-Looking Statement ADVENTRX cautions you that statements
included in this press release that are not a description of
historical facts are forward-looking statements that involve risks,
uncertainties, assumptions and other factors that, if they do not
materialize or prove to be accurate, could cause ADVENTRX's results
to differ materially from historical results or those expressed or
implied by such forward-looking statements. The potential risks and
uncertainties that could cause actual results to differ materially
include, but are not limited to: successfully educating new
executives and integrating new executives with existing executives
and management; uncertainties inherent in the drug development
process; the timing and success of clinical trials; the validity of
research results; the receipt of necessary approvals from the FDA
and other regulatory agencies; and other risks and uncertainties
more fully described in ADVENTRX's press releases and public
filings with the Securities and Exchange Commission. ADVENTRX's
public filings with the Securities and Exchange Commission are
available at http://www.sec.gov/. ADVENTRX does not intend to
update any forward-looking statement, including as set forth in
this press release, to reflect events or circumstances arising
after the date on which it was made. DATASOURCE: ADVENTRX
Pharmaceuticals, Inc. CONTACT: Ioana C. Hone of ADVENTRX
Pharmaceuticals, Inc., +1-858-552-0866; or Amy Martini of WeissComm
Partners, +1-212-301-7223, for ADVENTRX Pharmaceuticals, Inc. Web
site: http://www.adventrx.com/ Company News On-Call:
http://www.prnewswire.com/comp/920134.html
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024